Pfizer delivers final blow to Trump's hope for pre-election vaccine
The president’s last best hope for meeting that deadline fizzled Friday as Pfizer announced that it would not seek emergency authorization from the Food and Drug Administration before the third week of November. The company is the only frontrunner in the vaccine race that has said it could have proof its vaccine works by Nov. 3.
Since the beginning of the pandemic, federal health officials including infectious disease expert Anthony Fauci, CDC Director Robert Redfield and Health and Human Services Secretary Alex Azar have said that a vaccine is most likely by the end of the year or early 2021. Executives at Moderna, another frontrunner whose vaccine relies on a still-unproven technology, has said it will not be ready to submit an emergency authorization application to FDA until late November. Pfizer, meanwhile, continues to expand its trial — first to enroll thousands more adults, and most recently to include teens.
The agency revised its guidance to make sure drug makers submitted enough data to reveal any side effects from their shots, Hotez said. It"wasn’t done to punish the president, it was done to protect the public to ensure that we have vaccines that work and are safe," he said.
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Pfizer delivers final blow to Trump's hope for pre-election vaccineThere won’t be a coronavirus vaccine ready before Election Day, despite President Donald Trump’s repeated promises and vaccine makers’ breakneck speed.
Read more »
Pfizer says earliest COVID-19 vaccine application to U.S. regulators would be after electionPfizer Inc said on Friday it may file for U.S. authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November, making it unlikely a vaccine will be available before the U.S. election as President Donald Trump has promised...
Read more »
Pfizer sees emergency use filing for COVID-19 vaccine after U.S. electionPfizer Inc expects to provide safety data and file for authorization of the COVID-19 vaccine it is developing with German partner BioNTech in late November, delaying any clarity on the vaccine until after the Nov. 3 U.S. presidential election.
Read more »
'He’s getting a bit desperate': Trump tramples government boundaries as election nearsThe farther behind Donald Trump has fallen in the competition for campaign dollars, the more he’s milked government resources to make up the difference
Read more »